Related Experiment Video
Updated: Feb 27, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management
Mario Sznol1, Michael A Postow2, Marianne J Davies3
1Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.
Abstract:
Agents that modulate immune checkpoint proteins, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death receptor-1 (PD-1), have become a mainstay in cancer treatment. The clinical benefit afforded by immune checkpoint inhibitors can be accompanied by immune-related adverse events (irAE) that affect the skin, gastrointestinal tract, liver, and endocrine system. The types of irAEs associated with immune checkpoint inhibitors are generally consistent across tumor types. Immune-related endocrine events can affect the pituitary, thyroid, and adrenal glands, as well as other downstream target organs. These events are unique when compared with other irAEs because the manifestations are often irreversible. Immune-related endocrine events are typically grade 1/2 in severity and often present with non-specific symptoms, making them difficult to diagnose. The mechanisms underlying immune-related target organ damage in select individuals remain mostly undefined. Management includes close patient monitoring, appropriate laboratory testing for endocrine function, replacement of hormones, and consultation with an endocrinologist when appropriate. An awareness of the symptoms and management of immune-related endocrine events may aid in the safe and appropriate use of immune checkpoint inhibitors in clinical practice.
Insights
Immune checkpoint inhibitors for cancer can cause endocrine-related side effects affecting glands like the pituitary and thyroid. Early recognition and management are key for safe treatment.
Area of Science:
- Oncology
- Immunology
- Endocrinology
Background:
- Immune checkpoint inhibitors targeting CTLA-4 and PD-1 are crucial cancer therapies.
- These therapies can lead to immune-related adverse events (irAEs) affecting various organs.
- Endocrine irAEs impact the pituitary, thyroid, and adrenal glands, often irreversibly.
Purpose of the Study:
- To review the characteristics of immune-related endocrine events associated with immune checkpoint inhibitors.
- To highlight the diagnostic challenges and management strategies for these events.
- To emphasize the importance of awareness for safe clinical practice.
Main Methods:
- Literature review of immune checkpoint inhibitors and their associated endocrine adverse events.
- Analysis of the presentation, diagnosis, and management of immune-related endocrine events.
- Synthesis of current understanding regarding mechanisms and clinical implications.
Main Results:
- Immune-related endocrine events are common, often irreversible, and present with non-specific symptoms.
- Diagnosis can be challenging due to mild severity (Grade 1/2) and subtle manifestations.
- Management involves monitoring, hormone replacement, and specialist consultation.
Conclusions:
- Immune-related endocrine events require vigilant monitoring and prompt management.
- Understanding these events is crucial for the safe and effective use of immune checkpoint inhibitors.
- Further research into underlying mechanisms may improve patient outcomes.
Related Concept Videos
Tumor Immunotherapy
The Tumor Microenvironment
Acute Pancreatitis II: Clinical Manifestations and Management
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Psychoneuroimmunology: Diabetes and Cancer
Myocarditis III: Medical Management

